JAZZ Pharmaceuticals ANZ's Vyxeos (daunorubicin and cytarabine) has been approved to treat therapy-related acute myeloid leukaemia and AML-MRC.
Vyxeos must be initiated and monitored under the supervision of physicians experienced in the use of chemotherapeutic medicinal products.
The approval requires Vyxeos to be on the Black Triangle Scheme for five years from the date the product is first supplied in Australia.
The above article was sent to subscribers in Pharmacy Daily's issue from 15 Jun 22
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Jun 22
